# Study of Mirogabalin for Central Neuropathic Pain

> **NCT03901352** · PHASE3 · COMPLETED · sponsor: **Daiichi Sankyo Co., Ltd.** · enrollment: 300 (actual)

## Conditions studied

- Central Neuropathic Pain

## Interventions

- **DRUG:** Placebo
- **DRUG:** Mirogabalin

## Key facts

- **NCT ID:** NCT03901352
- **Lead sponsor:** Daiichi Sankyo Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-12
- **Primary completion:** 2020-12-28
- **Final completion:** 2020-12-28
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2024-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03901352

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03901352, "Study of Mirogabalin for Central Neuropathic Pain". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03901352. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*